Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Methotrexate

Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company0 个研究点目标入组 200 人开始时间: 2009年8月21日最近更新: 2013年9月9日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 200

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Age =18 years at the time of the signing of the ICF (or older as required by local regulation or ethics committees). 2. Subjects must be willing and able to comply with all the requirements of the study. 3. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at screening and baseline. WOCBP are defined as women who are biologically capable of becoming pregnant, including women who are using contraceptives or whose sexual partners are either sterile or using contraceptives. Women of non-childbearing potential are defined as either postmenopausal (history of amenorrhea for =52 weeks) or who are surgically sterile, such as after hysterectomy, bilateral oophorectomy, or tubal ligation (procedure performed =1 year before screening). This information must be documented in the subject’s source documents. 4. All WOCBP who have sexual intercourse with a non-surgically sterilized male must agree and commit to the use of hormonal contraception, double-barrier contraception (use of a condom with spermicide), or an intrauterine device throughout the entire study (defined as the time of the signing of the ICF through the conclusion of subject participation). Vasectomized partners must have had their vasectomy more than 6 months before study day 1. 5. All men (unless surgically sterile) who have sexual intercourse with a WOCBP must agree and commit to using a medically acceptable and highly effective method of contraception for the entire study (defined as the time of the signing of the ICF through the conclusion of subject participation). Medically acceptable and highly effective methods of contraception include properly used barrier forms of contraception. 6. Meets the American Rheumatism Association 1987 revised criteria for classification of RA at least 6 months prior to screening. 7. ACR functional class I through III. 8. At screening and baseline active RA as defined by = 5 swollen joints and = 5 tender joints (28 joint count) and either 1 or both of the following at screening: • C-reactive protein (CRP) =7 mg/L • Erythrocyte sedimentation rate (ESR) =28 mm/h 9. Must be seropositive as defined by a documented history of rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) positivity. If a documented history of RF or anti-CCP positivity is not available, RF and anti-CCP titers will be obtained at screening. 10. Must be receiving a MTX regimen (up to 25 mg weekly), according to standard medical practice and local regulation, for at least 12 weeks prior to baseline with or without a prior history of anti-TNF agent use. The dose and route of administration of MTX must be stable for at least 8 weeks prior to baseline and anticipated throughout the course of the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Pregnant women, nursing mothers, or women planning to become pregnant during the study. 2. Any cardiovascular, neurological, metabolic, immunological, hepatic, or renal condition that, in the opinion of the investigator, could be detrimental to subjects participating in this study, including any clinically important deviations from normal clinical laboratory values or important concurrent medical events. 3. Presence of active or suspected latent infection including any underlying diseases including open cutaneous ulcers that could predispose the subject to infection. 4. Severe heart failure (New York Heart Association [NYHA] class IV) or severe, uncontrolled cardiac disease. 5. Subjects with active tuberculosis or history of tuberculosis. A tuberculosis test, interpreted by the investigator according to local standards or country-specific-guidelines, must be performed during the screening visit for subjects with no documentation of tuberculosis test results available within 4 weeks before the screening visit. 6. Subjects with other rheumatic diseases, including but not limited to Lyme disease, psoriatic arthritis, spondyloarthropathy, systemic lupus erythematosus, systemic vasculitis, polymyositis, infectious arthritis, reactive arthritis, overlap syndrome and primary Sjögren's syndrome. 7. Cancer or history of cancer other than adequately treated cutaneous basal cell carcinoma or squamous cell carcinoma of the skin or in situ cervical cancer, with no evidence of recurrence. 8. History of alcohol or drug abuse that, in the opinion of the investigator, would interfere with the ability to comply with the study protocol. 9. Documented immunodeficiency disease, including but not limited to subjects with known human immunodeficiency virus (HIV) at the time of screening. 10. Subjects positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody (HepCAb), history of drug-induced liver injury, documented liver cirrhosis, or documented fibrosis at any time before the screening visit. 11. Any significant laboratory abnormality at screening, including the following: • Hemoglobin (Hb) <85 g/L • White blood cells (WBC) <3.50 x 10 power 9/L • Platelets <125 x 10 power 9/L or =1000 x 10 power 9/L • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 x the upper limit of normal (ULN) • Serum creatinine (SCr) >177 µmol/L • Lymphocyte count =0.5 x 10 power 9/L 12. Clinically significant finding on chest x-ray. Chest x-ray must be obtained during the screening period, unless a radiograph was obtained within 24 weeks prior to the baseline visit. 13. Prior use of B-cell depleting agents (e.g., rituximab). 14. Receipt of abatacept and/or tocilizumab. 15. Receipt of live attenuated vaccine =8 weeks prior to the screening visit. 16. Known hypersensitivity to mouse immunoglobulin, mouse/human chimeric immunoglobulin, or other biopharmaceutical proteins. 17. Hypersensitivity to corticosteroids and/or acetaminophen/paracetamol and/or diphenhydramine (or equivalent). 18. Receipt of the following within 24 weeks before the baseline visit: • Any investigational drug, including biologics • Any cytotoxic or immunosuppressive agent, including cyclophosphamide or chlorambucil • Intravenous immunoglobulin (IVIG) • Prosorba column (extracorporeal immunoadsorption protein A column) • Intra-articular (IA) hyaluronic acid injections 19. Receipt of the following within 12 weeks before the baseline visit: • An

研究者

发起方

Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company

相似试验

进行中（未招募）

不适用

Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of MethotrexateRheumatoid arthritis (seropositive)MedDRA version: 9.1Level: LLTClassification code 10040107Term: Seropositive rheumatoid arthritis

EUCTR2009-010516-15-HUWyeth Research Division of Wyeth Pharmaceuticals Inc.200

进行中（未招募）

1 期

EUCTR2009-010516-15-GRWyeth Research Division of Wyeth Pharmaceuticals Inc.209

进行中（未招募）

1 期

Efficacy and safety evaluation of umbilical cord mesenchymal stem cells for the treatment of patients with respiratory failure due to coronavirus (COVID-19)

EUCTR2020-001505-22-ESBanc de Sang i Teixits25

进行中（未招募）

不适用

Different doses of Udenafil tablets against portal hypertension for patients with liver cirrhosis

EUCTR2006-006393-14-ATDr. Falk Pharma GmbH220

进行中（未招募）

1 期

Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypertension Preceded by an Open-Label Pilot Phase - Udenafil tablets vs. placebo in portal hypertensioPortal hypertension, liver cirrhosisMedDRA version: 13.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 13.1Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disorders

EUCTR2006-006393-14-LTDr. Falk Pharma GmbH220